Background: Censoring by the study sponsor of clinical endpoint events in indication-seeking randomized trials represents a controversial approach since the reported data may be biased in favor of experimental agents due to the obvious conflict of interest. The frequency of drug discontinuation and rates of consent withdrawal may also impact the trial outcomes. Purpose: To assess patterns of event reporting dependent on sponsor censoring dates, drug discontinuation and consent withdrawal in the PLATO trial. Methods: Analysis of theFood and Drug Administration Complete Response Review for ticagrelor. Results: Excluding adjudicated deaths, the distribution for clopidogrel appears more uniform while that for ticagrelor was skewed to the right, suggesting more events were reported after the sponsor censoring end date. PLATO investigators reported 16 unmatched primary endpoint events for ticagrelor immediately following the sponsor censoring date. Twenty-six out of 30 unreported events following early drug discontinuation occurred amongst patients using ticagrelor. More ticagrelor patients withdrew consent (Δ = 47), or were ‘not willing’ to complete the study (Δ = 87) when compared to clopidogrel. Conclusions: Site-reported primary endpoints were unequally distributed for clopidogrel and ticagrelor in the PLATO trial. This pattern suggests the importance of questioning the impact of sponsor-mediated censoring on event reporting by investigators in indication-seeking trials. In PLATO, this pattern seems to have favored the experimental drug and may require further assessment.

Keywords:
Ticagrelor, Clopidogrel, Clinical trials, Monitoring, Antiplatelet therapy
1.
Hamrell MR: Raising suspicions with the Food and Drug Administration: detecting misconduct. Sci Eng Ethics 2010;16:697–704.
2.
Pronker E, Geerts BF, Cohen A, Pieterse H: Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials. Br J Clin Pharmacol 2011;71:467–470.
3.
Goldenberg NA, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AG, Skene AM, Cutler NR, Hiatt WR, Antithrombotic Trials Leadership and Steering Group: Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood 2011;117:2089–2092.
4.
Silverman H: Ethical issues during the conduct of clinical trials. Proc Am Thorac Soc 2007;4:180–184.
5.
Williams GW: The other side of clinical trial monitoring; assuring data quality and procedural adherence. Clin Trials 2006;3:530–537.
6.
The FDA Ticagrelor Review of Complete Response: Drug approval package. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000TOC.cfm
7.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, the PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
9.
Serebruany VL: The FDA prasugrel review: adjudication of myocardial infarction controversy. Cardiology 2009;114:126–129.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.